H J M Smelt1, J F Smulders2, M Said2, S W Nienhuijs2, A K Boer3. 1. Department of Dietetics, Catharina Hospital, Michelangelolaan 2, P.O. Box 1350, 5602 ZA, Eindhoven, The Netherlands. marieke.smelt@catharinaziekenhuis.nl. 2. Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands. 3. Department of Clinical Chemistry-Endocrinology, Catharina Hospital, Eindhoven, The Netherlands.
Abstract
BACKGROUND: Vitamin B12 deficiency is common after bariatric surgery. Vitamin B12 is a poor predictor of functional vitamin B12 status, since deficiencies might even occur within the reference limits. Therefore, vitamin B12 deficiencies with serum vitamin B12 levels are between 140 and 200 pmol/L remain undetected. Methylmalonic acid (MMA), however, will detect these deficiencies as accumulates due to functional intracellular vitamin B12 deficiencies. MMA is a relative expensive analysis and is therefore not generally available. To lower the costs, we only request MMA when vitamin B12 levels are between these levels. As a result, more biochemical deficiencies are found. However, it was not known whether bariatric patients with vitamin B12 levels between 140 and 200 pmol/L would benefit from supplementation. METHOD: Bariatric patients with vitamin B12 levels between 140 and 200 pmol/L with (n = 45) and without (n = 45) intramuscular hydroxocobalamin injections were compared. RESULTS: Treated patients showed a significant increase of vitamin B12 levels (P < 0.001) and a significant decrease in MMA levels (P < 0.001). Biochemical improvement occurs in both patients with and without clinical symptoms. The control group showed a significant increase of MMA levels (P < 0.001). To examine whether biochemical benefits of vitamin B12 supplementation are correlated with clinical improvement, patient records were checked for complaints. Complaints were disappeared after treatment, while no improvement was seen in untreated patients. CONCLUSION: This study shows that all bariatric patients with vitamin B12 levels between 140 and 200 pmol/L benefit clinical and biochemical from vitamin B12 supplementation, regardless the MMA levels.
BACKGROUND: Vitamin B12 deficiency is common after bariatric surgery. Vitamin B12 is a poor predictor of functional vitamin B12 status, since deficiencies might even occur within the reference limits. Therefore, vitamin B12 deficiencies with serum vitamin B12 levels are between 140 and 200 pmol/L remain undetected. Methylmalonic acid (MMA), however, will detect these deficiencies as accumulates due to functional intracellular vitamin B12 deficiencies. MMA is a relative expensive analysis and is therefore not generally available. To lower the costs, we only request MMA when vitamin B12 levels are between these levels. As a result, more biochemical deficiencies are found. However, it was not known whether bariatric patients with vitamin B12 levels between 140 and 200 pmol/L would benefit from supplementation. METHOD: Bariatric patients with vitamin B12 levels between 140 and 200 pmol/L with (n = 45) and without (n = 45) intramuscular hydroxocobalamin injections were compared. RESULTS: Treated patients showed a significant increase of vitamin B12 levels (P < 0.001) and a significant decrease in MMA levels (P < 0.001). Biochemical improvement occurs in both patients with and without clinical symptoms. The control group showed a significant increase of MMA levels (P < 0.001). To examine whether biochemical benefits of vitamin B12 supplementation are correlated with clinical improvement, patient records were checked for complaints. Complaints were disappeared after treatment, while no improvement was seen in untreated patients. CONCLUSION: This study shows that all bariatric patients with vitamin B12 levels between 140 and 200 pmol/L benefit clinical and biochemical from vitamin B12 supplementation, regardless the MMA levels.
Authors: Radmila Levinson; Jon B Silverman; Jennifer G Catella; Iwona Rybak; Hina Jolin; Kellene Isom Journal: Obes Surg Date: 2013-07 Impact factor: 4.129
Authors: Robert Clarke; Helga Refsum; Jacqueline Birks; John Grimley Evans; Carole Johnston; Paul Sherliker; Per M Ueland; Joern Schneede; Joseph McPartlin; Ebba Nexo; John M Scott Journal: Am J Clin Nutr Date: 2003-05 Impact factor: 7.045
Authors: Robert Clarke; Paul Sherliker; Harold Hin; Ebba Nexo; Anne Mette Hvas; Joern Schneede; Jacqueline Birks; Per M Ueland; Kathleen Emmens; John M Scott; Anne M Molloy; John Grimley Evans Journal: Clin Chem Date: 2007-03-15 Impact factor: 8.327
Authors: A E Sumner; M M Chin; J L Abrahm; G T Berry; E J Gracely; R H Allen; S P Stabler Journal: Ann Intern Med Date: 1996-03-01 Impact factor: 25.391
Authors: Hendrika J M Smelt; Saskia van Loon; Sjaak Pouwels; Arjen-Kars Boer; Johannes F Smulders; Edo O Aarts Journal: Obes Surg Date: 2020-02 Impact factor: 4.129
Authors: Bruce H R Wolffenbuttel; Hanneke J C M Wouters; M Rebecca Heiner-Fokkema; Melanie M van der Klauw Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2019-05-27
Authors: Mary O'Kane; Helen M Parretti; Jonathan Pinkney; Richard Welbourn; Carly A Hughes; Jessica Mok; Nerissa Walker; Denise Thomas; Jennifer Devin; Karen D Coulman; Gail Pinnock; Rachel L Batterham; Kamal K Mahawar; Manisha Sharma; Alex I Blakemore; Iris McMillan; Julian H Barth Journal: Obes Rev Date: 2020-08-02 Impact factor: 9.213